FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620163710> ?p ?o ?g. }

• W2620163710 endingPage "51640" @default.
• W2620163710 startingPage "51630" @default.
• W2620163710 abstract "// Minghui Zhang 1, * , Dalong Wang 2, 3, * , Qi Sun 4, * , Haihong Pu 1 , Yan Wang 5 , Shu Zhao 1 , Yan Wang 1 and Qiangyuan Zhang 1 1 Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China 2 Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150040, China 3 Department of PET/CT, Harbin Medical University Cancer Hospital, Harbin 150081, China 4 Department of Radiology, Harbin Medical University Cancer Hospital, Harbin 150081, China 5 Department of Medical Oncology, Heilongjiang Provincial Hospital, Harbin 150000, China * These authors have contributed equally to this work Correspondence to: Qiangyuan Zhang, email: zhma1965210@163.com Keywords: programmed cell death ligand 1, squamous cell carcinoma, prognostic factor, PET-CT Received: March 14, 2017      Accepted: April 28, 2017      Published: May 29, 2017 ABSTRACT Programmed cell death-ligand 1 (PD-L1) expression is commonly observed in non-small cell lung cancer (NSCLC). The prognostic value of PD-L1 expression and the maximum standardized uptake value (SUVmax) on 18F-Fluorodeoxyglucose positron emission tomography ( 18 FDG-PET) in surgical pulmonary squamous cell carcinoma(SCC)remains unclear. Furthermore, the correlation between the SUVmax and PD-L1 expression has not been assessed. Thus, the purpose of this study was to investigate the correlation between PD-L1 expression and the SUVmax on 18 FDG-PET and to examine the prognostic significance of PD-L1 expression and the SUVmax in surgical pulmonary SCC. Expression of PD-L1 was examined in 84 patients with resected SCC using immunohistochemistry. Positive PD-L1 expression in tumour cells was observed in 58.3% (49/84) of patients with SCC. High PD-L1 expression levels were significantly correlated with histological differentiation (P=0.006), and a high SUVmax was associated with histological differentiation (P=0.037), and lymph node metastasis (P=0.025).Spearman’s test showed that there was a significant correlation between PD-L1 expression levels and the SUVmax. High PD-L1 expression levels and a high SUVmax were both independent risks factors for poor overall survival. Our results suggested that high PD-L1 expression levels and a high SUVmax was associated with poor prognosis in surgical pulmonary SCC. The existence of a statistically significant correlation between the SUVmax and PD-L1 expression levels justifies exploring the usefulness of the SUVmax as a predictor of PD-1/PD-L1 inhibitor activity." @default.
• W2620163710 created "2017-06-05" @default.
• W2620163710 creator A5003642180 @default.
• W2620163710 creator A5016549587 @default.
• W2620163710 creator A5040075588 @default.
• W2620163710 creator A5062209023 @default.
• W2620163710 creator A5063982212 @default.
• W2620163710 creator A5067618279 @default.
• W2620163710 creator A5087847070 @default.
• W2620163710 date "2017-05-29" @default.
• W2620163710 modified "2023-10-17" @default.
• W2620163710 title "Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma" @default.
• W2620163710 cites W1416776357 @default.
• W2620163710 cites W1520095978 @default.
• W2620163710 cites W1877385522 @default.
• W2620163710 cites W1879746506 @default.
• W2620163710 cites W2002052629 @default.
• W2620163710 cites W2010121426 @default.
• W2620163710 cites W2010596067 @default.
• W2620163710 cites W2048974336 @default.
• W2620163710 cites W2077923688 @default.
• W2620163710 cites W2103198152 @default.
• W2620163710 cites W2122542423 @default.
• W2620163710 cites W2151570232 @default.
• W2620163710 cites W2156353875 @default.
• W2620163710 cites W2160834915 @default.
• W2620163710 cites W2172770673 @default.
• W2620163710 cites W2177527758 @default.
• W2620163710 cites W2187430385 @default.
• W2620163710 cites W2201672580 @default.
• W2620163710 cites W2226313998 @default.
• W2620163710 cites W2235523093 @default.
• W2620163710 cites W2279684443 @default.
• W2620163710 cites W2292383635 @default.
• W2620163710 cites W2296139876 @default.
• W2620163710 cites W2297761236 @default.
• W2620163710 cites W2299585884 @default.
• W2620163710 cites W2300582328 @default.
• W2620163710 cites W230538906 @default.
• W2620163710 cites W2322556414 @default.
• W2620163710 cites W2323356988 @default.
• W2620163710 cites W2341622444 @default.
• W2620163710 cites W2345307430 @default.
• W2620163710 cites W2470043979 @default.
• W2620163710 cites W2471398347 @default.
• W2620163710 cites W2485997743 @default.
• W2620163710 cites W2499029168 @default.
• W2620163710 cites W2513200835 @default.
• W2620163710 cites W2557604612 @default.
• W2620163710 cites W2560367415 @default.
• W2620163710 cites W2564538766 @default.
• W2620163710 cites W2572174216 @default.
• W2620163710 cites W2581827633 @default.
• W2620163710 cites W2582960575 @default.
• W2620163710 cites W2586522715 @default.
• W2620163710 cites W2589193607 @default.
• W2620163710 doi "https://doi.org/10.18632/oncotarget.18257" @default.
• W2620163710 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5584275" @default.
• W2620163710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28881674" @default.
• W2620163710 hasPublicationYear "2017" @default.
• W2620163710 type Work @default.
• W2620163710 sameAs 2620163710 @default.
• W2620163710 citedByCount "48" @default.
• W2620163710 countsByYear W26201637102017 @default.
• W2620163710 countsByYear W26201637102018 @default.
• W2620163710 countsByYear W26201637102019 @default.
• W2620163710 countsByYear W26201637102020 @default.
• W2620163710 countsByYear W26201637102021 @default.
• W2620163710 countsByYear W26201637102022 @default.
• W2620163710 countsByYear W26201637102023 @default.
• W2620163710 crossrefType "journal-article" @default.
• W2620163710 hasAuthorship W2620163710A5003642180 @default.
• W2620163710 hasAuthorship W2620163710A5016549587 @default.
• W2620163710 hasAuthorship W2620163710A5040075588 @default.
• W2620163710 hasAuthorship W2620163710A5062209023 @default.
• W2620163710 hasAuthorship W2620163710A5063982212 @default.
• W2620163710 hasAuthorship W2620163710A5067618279 @default.
• W2620163710 hasAuthorship W2620163710A5087847070 @default.
• W2620163710 hasBestOaLocation W26201637101 @default.
• W2620163710 hasConcept C121608353 @default.
• W2620163710 hasConcept C126322002 @default.
• W2620163710 hasConcept C143998085 @default.
• W2620163710 hasConcept C199374082 @default.
• W2620163710 hasConcept C2775842073 @default.
• W2620163710 hasConcept C2776256026 @default.
• W2620163710 hasConcept C2989005 @default.
• W2620163710 hasConcept C71924100 @default.
• W2620163710 hasConceptScore W2620163710C121608353 @default.
• W2620163710 hasConceptScore W2620163710C126322002 @default.
• W2620163710 hasConceptScore W2620163710C143998085 @default.
• W2620163710 hasConceptScore W2620163710C199374082 @default.
• W2620163710 hasConceptScore W2620163710C2775842073 @default.
• W2620163710 hasConceptScore W2620163710C2776256026 @default.
• W2620163710 hasConceptScore W2620163710C2989005 @default.
• W2620163710 hasConceptScore W2620163710C71924100 @default.
• W2620163710 hasIssue "31" @default.
• W2620163710 hasLocation W26201637101 @default.
• W2620163710 hasLocation W26201637102 @default.

• next